发布时间：2026-03-27 11:33
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF (trifarotene)1-8
Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil in different skin types9
Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14
A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare

ZUG, Swi
=*=*=*=*=*=
当前为第1/17页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页